Revolutionizing Cardiovascular Care for the Elderly: A Digital, Inclusive, and Safer Approach
The aging population deserves better cardiovascular care, and experts are leading the way. At the AHA 2025 conference, a compelling case was made for transforming how we care for older adults with heart conditions. It's time to embrace digital innovation, inclusivity, and safer medication practices to improve patient outcomes.
But here's the catch: Older adults are often left behind in cardiovascular research and clinical trials. This underrepresentation has led to unique challenges in managing hypertension and an increased risk of polypharmacy and overtreatment. So, how can we bridge this gap?
Overcoming Digital Barriers in Hypertension Management
John Dodson, MD, MPH, shared insights on how digital health can be a game-changer. While mobile devices are increasingly used for health management, hypertension control in older adults remains low due to various factors. Comorbidities, limited mobility, and medication adherence challenges are significant hurdles. Dodson emphasized that understanding and addressing these real-world barriers is crucial for the success of digital health tools.
A common issue? Many patients find new technology frustrating. Privacy concerns and resistance to change are understandable, but they hinder progress. Physical limitations, such as impaired vision or hearing loss, and cognitive decline further complicate matters. Dodson's team conducted trials that revealed the importance of patient engagement. In the RESILIENT trial, mobile health-based cardiac rehabilitation showed potential, but patient motivation and support were key.
Expanding Representation in Coronary Disease Trials
Michael Nanna, MD, MHS, highlighted the persistent underrepresentation of older adults in coronary artery disease research. While age-based exclusions are less common, older adults are still indirectly excluded due to various factors like comorbidities and transportation issues. Nanna stressed the importance of enrolling patients across the biological aging spectrum for more generalizable results.
The LIVEBETTER study stands out for its unique design. By involving patients and caregivers in selecting the primary endpoint, the trial focuses on global quality of life, an often-neglected outcome. Engaging caregivers is crucial for successful enrollment, as demonstrated in LIVEBETTER, where caregivers were enrolled alongside patients.
Deprescribing and Polypharmacy: Finding the Right Balance
Mark Effron, MD, brought attention to the delicate balance between medication therapy and polypharmacy. In complex cases, patients may be prescribed numerous medications, creating new health risks. Effron highlighted the 'inherent tension' between treating cardiovascular disease and managing the side effects of multiple drugs. Clinicians must carefully consider the benefits and harms of each medication, especially when they conflict with patient goals.
Therapeutic competition is a real concern. Treating one condition may worsen another. For older adults with comorbidities, close monitoring and patient-centered care are essential. Effron emphasized the need to avoid overtreatment, as it can lead to unintended consequences. Deprescribing trials and n-of-1 trials offer promising approaches to personalized medication decisions, ensuring a safer and more tailored treatment journey.
The bottom line: As we strive for better cardiovascular care for older adults, digital tools, inclusive trials, and deprescribing strategies are powerful weapons in our arsenal. But it's a delicate balance, and we must navigate these innovations with caution. What do you think? Are these approaches the future of cardiovascular care for the elderly, or do we need to consider other perspectives? Share your thoughts and let's keep the conversation going!
